Biophytis SA Overview
Pro stress-test →Biophytis is a biotechnology entity specialized in the development of drug candidates to treat ageing diseases, with two programs focused on sarcopenia (loss of muscle functionality) and Age Related Macular Degeneration (ARMD). The company operates as a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases.
Strategic Profile
Pro stress-test →The company's product pipeline includes Sarconeos (BIO101), a first-in-class drug candidate for the treatment of sarcopenic obesity. The company develops drug candidates based on SARCOB and MACULIA technological platforms. As a clinical-stage biotech with limited market cap, Biophytis faces significant execution risk but operates in the high-value age-related disease therapeutics space.
Competitive Landscape
Pro stress-test →Biophytis operates in the competitive age-related disease therapeutics space. Direct competitors include Novartis (with anti-aging research initiatives), Unity Biotechnology (senolytic focus), and Juvenescence (longevity-focused biotech platforms). The sarcopenia and ARMD segments also attract attention from larger pharmaceutical players including Eli Lilly (with GLP-1 derivative programs) and Roche (ophthalmology focus). Biophytis' differentiation rests on its dual-platform approach and lead asset stage, though larger-cap competitors have greater resources for clinical advancement.
Industry Context
Biophytis SA operates in Clinical-Stage Biotechnology / Age-Related Disease Therapeutics.
Key facts
Founded: N/A · Headquarters: Paris, France · Employees: N/A · Revenue: N/A · Market cap: €3.08m